Carboplatin Treatment Options

A collection of 1672 research studies where Carboplatin is the interventional treatment. These studies are located in the United States. Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.

Home

All Treatments

Carboplatin

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

APG-115 in Salivary Gland Cancer Trial

NCT03781986

Active Not Recruiting

This is a phase I/II trial to evaluate the efficacy of APG-115 +/- Carboplatin for the treatment p53 wild-type malignant salivary gland cancer. Part 1 consisted of 2 arms, arm A (APG-115 monotherapy) and arm B (APG-115 + Carboplatin) and was terminated early. Part 2 is a single arm study (APG-115 monotherapy).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/13/2025

Locations: Moffitt Cancer Center, Tampa, Florida +2 locations

Conditions: Malignant Salivary Gland Cancer, Salivary Gland Cancer

Learn More ›

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT02998528

Completed

The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC. This study has multiple primary endpoints.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/13/2025

Locations: Local Institution - 0121, Glendale, Arizona +139 locations

Local Institution - 0121, Glendale, Arizona

Local Institution - 0081, Los Angeles, California

Local Institution - 0025, Denver, Colorado

Local Institution - 0007, Plainville, Connecticut

Local Institution - 0173, Hollywood, Florida

Local Institution - 0136, Miami, Florida

Local Institution - 0054, Orlando, Florida

Orlando Health, Inc., Orlando, Florida

Indian River Medical Center, Vero Beach, Florida

Northwest Georgia Oncology Center, P.C., Marietta, Georgia

Local Institution - 0015, Chicago, Illinois

Local Institution - 0002, Chicago, Illinois

Illinois Cancer Specialists, Niles, Illinois

Local Institution - 0171, Fort Wayne, Indiana

Local Institution - 0170, Lexington, Kentucky

Local Institution - 0186, Louisville, Kentucky

University Medical Center New Orleans, New Orleans, Louisiana

Local Institution - 0151, Baltimore, Maryland

Local Institution - 0001, Baltimore, Maryland

Local Institution - 0008, Boston, Massachusetts

Southcoast Center For Cancer, Fairhaven, Massachusetts

Local Institution - 0006, Newton, Massachusetts

Local Institution - 0012, Detroit, Michigan

Local Institution - 0090, Hattiesburg, Mississippi

St Vincent Frontier Cancer Center, Billings, Montana

Local Institution - 0032, Las Vegas, Nevada

Local Institution - 0009, Hackensack, New Jersey

Valley Hospital Luckow Pavili, Westwood, New Jersey

Local Institution - 0027, Albany, New York

Local Institution - 0011, New York, New York

Local Institution - 0140, High Point, North Carolina

Christ Hospital, Cincinnati, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Local Institution - 0149, Zanesville, Ohio

Kaiser Permanente, Portland, Oregon

Local Institution - 0139, Portland, Oregon

Local Institution - 0010, Philadelphia, Pennsylvania

Local Institution - 0018, Pittsburgh, Pennsylvania

Local Institution - 0013, Charleston, South Carolina

Local Institution - 0021, Charleston, South Carolina

Local Institution - 0146, Greenville, South Carolina

Local Institution - 0092, Nashville, Tennessee

Local Institution - 0005, Nashville, Tennessee

Local Institution - 0035, Austin, Texas

Texas Oncology, Bedford, Texas

Local Institution - 0153, Fort Bliss, Texas

Local Institution - 0106, Houston, Texas

Southwest Cancer Center, Lubbock, Texas

Texas Cancer Center - Sherman, Sherman, Texas

Local Institution - 0143, Tyler, Texas

Local Institution - 0026, Waco, Texas

Intermountain Medical Center, Murray, Utah

Southwest Regional Cancer Clinic, Saint George, Utah

Local Institution - 0003, Salt Lake City, Utah

Local Institution - 0135, Burlington, Vermont

Local Institution - 0125, Fairfax, Virginia

Local Institution - 0198, Fredericksburg, Virginia

Local Institution - 0022, Capital Federal, Buenos Aires

Local Institution - 0023, Ciudad Autonoma De Buenos Aire, Buenos Aires

Local Institution - 0079, Brasilia, Distrito Federal

Local Institution - 0077, Belo Horizonte, Minas Gerais

Local Institution - 0076, Ijui, RIO Grande DO SUL

Local Institution - 0073, Porto Alegre, RIO Grande DO SUL

Fundacao Pio Xii Hosp Cancer De Barretos, Barretos, Sao Paulo

Local Institution - 0075, Rio de Janeiro, Not set

Local Institution - 0095, Gatineau, Quebec

Local Institution - 0138, Montreal, Quebec

Local Institution - 0017, Montreal, Quebec

Local Institution - 0052, Trois-Rivieres, Quebec

Local Institution - 0016, Saskatoon, Saskatchewan

Local Institution - 0161, Beijing, Beijing

Local Institution, Beijing, Beijing

Local Institution - 0156, Beijing, Beijing

Local Institution - 0190, Guangzhou, Guangdong

Local Institution - 0192, Changsha, Hunan

Local Institution - 0175, Changsha, Hunan

Local Institution - 0193, Changsha, Hunan

Local Institution - 0179, Nanchang, Jiangxi

Local Institution - 0166, Nanchang, Jiangxi

Local Institution, Changchun, Jilin

Local Institution - 0159, XiAn, Shan1xi

Local Institution - 0180, Xian, Shan3xi

Local Institution - 0160, Shanghai, Shanghai

Local Institution - 0178, Chengdu, Sichuan

Local Institution - 0163, Tianjin, Tianjin

Local Institution - 0189, Hangzhou, Zhejiang

Local Institution - 0183, Hangzhou, Zhejiang

Local Institution - 0182, Hangzhou, Zhejiang

Local Institution - 0165, Shanghai, Not set

Local Institution - 0059, Marseille Cedex 20, Not set

Local Institution - 0112, Paris Cedex 5, Not set

Local Institution - 0060, Paris, Not set

Local Institution - 0064, Pierre Benite Cedax, Not set

Local Institution - 0061, Rennes Cedex 9, Not set

Local Institution - 0113, Strasbourg, Not set

Local Institution - 0058, Toulouse, Not set

Local Institution - 0062, Tours Cedex 09, Not set

Local Institution - 0019, Athens, Not set

Local Institution - 0122, Thessaloniki, Not set

Local Institution, Budapest, Not set

Local Institution, Szekesfehervar, Not set

Local Institution - 0068, Bari, Not set

Local Institution - 0080, Genova, Not set

Local Institution - 0070, Perugia, Not set

Local Institution - 0066, Ravenna, Not set

Local Institution - 0067, Roma, Not set

Local Institution - 0131, Nagoya-shi, Aichi

Local Institution - 0118, Kashiwa-shi, Chiba

Local Institution - 0111, Kitakyushu-shi, Fukuoka

Local Institution - 0110, Fukushima-shi, Fukushima

Local Institution - 0109, Hiroshima-Shi, Hiroshima

Local Institution - 0147, Sapporo-shi, Hokkaido

Local Institution - 0133, Kobe-shi, Hyogo

Local Institution - 0123, Yokohama-shi, Kanagawa

Local Institution - 0148, Sendai-shi, Miyagi

Local Institution - 0127, Osaka-shi, Osaka

Local Institution - 0119, Sakai-shi, Osaka

Local Institution - 0132, Sunto-gun, Shizuoka

Local Institution - 0126, Bunkyo-ku, Tokyo

Local Institution - 0120, Shinjuku-ku, Tokyo

Local Institution - 0108, Osaka, Not set

Local Institution - 0124, Tokyo, Not set

Local Institution - 0097, Busan, Not set

Local Institution - 0098, Hwasun, Not set

Local Institution - 0105, Seoul, Not set

Local Institution - 0042, Amsterdam, Not set

Local Institution - 0043, Groningen, Not set

Local Institution - 0050, Craiova, Not set

Local Institution - 0051, Romania, Not set

Local Institution - 0069, Sector 2, Not set

Local Institution - 0028, Barcelona, Not set

Local Institution - 0029, Madrid, Not set

Local Institution - 0031, Majadahonda - Madrid, Not set

Local Institution - 0102, New Taipei City, Not set

Local Institution - 0107, Taichung, Not set

Local Institution - 0099, Taipei, Not set

Local Institution - 0100, Taipei, Not set

Local Institution - 0093, Adana, Not set

Local Institution - 0084, Ankara, Not set

Local Institution - 0115, Istanbul, Not set

Conditions: Non Small Cell Lung Cancer

Learn More ›

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

NCT03509012

Completed

This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors

Gender:

ALL

Ages:

Between 18 years and 110 years

Trial Updated:

01/13/2025

Locations: Research Site, Tucson, Arizona +15 locations

Conditions: Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Learn More ›

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

NCT02375204

Active Not Recruiting

This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned after a period of improvement or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from d... Read More

Gender:

MALE

Ages:

14 years and above

Trial Updated:

01/09/2025

Locations: Children's Hospital of Alabama, Birmingham, Alabama +124 locations

Children's Hospital of Alabama, Birmingham, Alabama

UC San Diego Moores Cancer Center, La Jolla, California

Loma Linda University Medical Center, Loma Linda, California

USC / Norris Comprehensive Cancer Center, Los Angeles, California

Kaiser Permanente-Oakland, Oakland, California

Stanford Cancer Institute Palo Alto, Palo Alto, California

UCSF Medical Center-Mission Bay, San Francisco, California

Alfred I duPont Hospital for Children, Wilmington, Delaware

MedStar Georgetown University Hospital, Washington, District of Columbia

University of Florida Health Science Center - Gainesville, Gainesville, Florida

Nemours Children's Clinic-Jacksonville, Jacksonville, Florida

Nicklaus Children's Hospital, Miami, Florida

Miami Cancer Institute, Miami, Florida

Arnold Palmer Hospital for Children, Orlando, Florida

Johns Hopkins All Children's Hospital, Saint Petersburg, Florida

Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

Northwestern University, Chicago, Illinois

Rush University Medical Center, Chicago, Illinois

University of Illinois, Chicago, Illinois

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

Ascension Via Christi Hospitals Wichita, Wichita, Kansas

Cancer Center of Kansas - Wichita, Wichita, Kansas

Ochsner Medical Center Jefferson, New Orleans, Louisiana

Dana-Farber Cancer Institute, Boston, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Spectrum Health at Butterworth Campus, Grand Rapids, Michigan

University of Michigan Health - West, Wyoming, Michigan

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota

Mayo Clinic in Rochester, Rochester, Minnesota

Washington University School of Medicine, Saint Louis, Missouri

Nebraska Methodist Hospital, Omaha, Nebraska

Summerlin Hospital Medical Center, Las Vegas, Nevada

Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey

Hackensack University Medical Center, Hackensack, New Jersey

Memorial Sloan Kettering Monmouth, Middletown, New Jersey

Saint Joseph's Regional Medical Center, Paterson, New Jersey

Roswell Park Cancer Institute, Buffalo, New York

Memorial Sloan Kettering Commack, Commack, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Memorial Sloan Kettering Nassau, Uniondale, New York

Memorial Sloan Kettering Westchester, West Harrison, New York

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

Rhode Island Hospital, Providence, Rhode Island

Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina

Medical University of South Carolina, Charleston, South Carolina

Prisma Health Cancer Institute - Easley, Easley, South Carolina

Saint Francis Hospital, Greenville, South Carolina

BI-LO Charities Children's Cancer Center, Greenville, South Carolina

Prisma Health Cancer Institute - Butternut, Greenville, South Carolina

Prisma Health Cancer Institute - Faris, Greenville, South Carolina

Prisma Health Greenville Memorial Hospital, Greenville, South Carolina

Saint Francis Cancer Center, Greenville, South Carolina

Prisma Health Cancer Institute - Eastside, Greenville, South Carolina

Prisma Health Cancer Institute - Greer, Greer, South Carolina

Prisma Health Cancer Institute - Seneca, Seneca, South Carolina

Spartanburg Medical Center, Spartanburg, South Carolina

Saint Jude Children's Research Hospital, Memphis, Tennessee

The Children's Hospital at TriStar Centennial, Nashville, Tennessee

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

El Paso Children's Hospital, El Paso, Texas

M D Anderson Cancer Center, Houston, Texas

Seattle Children's Hospital, Seattle, Washington

Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin

Marshfield Medical Center-Marshfield, Marshfield, Wisconsin

Medical College of Wisconsin, Milwaukee, Wisconsin

Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin

Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin

Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin

Marshfield Medical Center - Weston, Weston, Wisconsin

Royal Prince Alfred Hospital, Camperdown, New South Wales

Princess Alexandra Hospital, Woolloongabba, Queensland

Box Hill Hospital, Box Hill, Victoria

Peter MacCallum Cancer Centre, Melbourne, Victoria

Institut Jules Bordet, Anderlecht, Not set

University Hospital Saint Luc, Brussels, Not set

Rigshospitalet University Hospital, Copenhagen, Not set

Centre Leon Berard, Lyon, Not set

Institut Paoli Calmettes, Marseille, Not set

Hopital Tenon/Assistance Publique - Hopitaux de Paris, Paris, Not set

CHRU Strasbourg - Hospital Civil, Strasbourg, Not set

Center Claudius Regaud, Toulouse, Not set

Centre Alexis Vautrin, Vandoeuvre-les-Nancy, Not set

Gustave Roussy, Villejuif, Not set

Technical University Dresden, Dresden, Saxony

University of Berlin Charite Campus Benjamin Franklin, Berlin, Not set

University of Dusseldorf, Dusseldorf, Not set

University of Essen, Essen, Not set

University Medical Center Hamburg-Eppendorf, Hamburg, Not set

UniversitaetsKlinikum Heidelberg, Heidelberg, Not set

GK-Mittelrhein Saint Martin's, Koblenz, Not set

Philipps University Marburg, Marburg, Not set

Rotkreuzklinikum Munchen, Munich, Not set

Klinikum Nurnberg Nord, Nurnberg, Not set

University Hospital Ulm, Ulm, Not set

Saint James Hospital, Dublin, Not set

Ospedale di Circolo di Busto Arsizio, Busto Arsizio, Not set

Istituto Scientifico Romagnolo, Meldola, Not set

Istituto Nazionale Tumori, Milano, Not set

San Matteo Hospital, Pavia, Not set

The Netherlands Cancer Institute, Amsterdam, Not set

University Medical Center Groningen, Groningen, Not set

Radboud University Nijmegen Medical Centre, Nijmegen, Not set

Hospital De La Santa Creu I Sant Pau, Barcelona, Not set

Duran i Reynals Hospital-Catalan Institute of Oncology, Barcelona, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital General Universitario Morales Meseguer, Murcia, Not set

Inselspital, Bern, Not set

Hopitaux Universitaires de Geneve, Geneva, Not set

University Hospital Zurich, Zurich, Not set

Saint Bartholomew's Hospital, London, England

Christie Hospital, Manchester, England

Weston Park Hospital, Sheffield, England

Southampton General Hospital, Southampton, England

Saint James's University Hospital, West Yorkshire, England

Beatson Oncology Center, Glasgow, Scotland

Nottingham City Hospital, Nottingham, Not set

The Royal Marsden NHS Foundation Trust - Sutton, Surrey, Not set

Conditions: Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma

Learn More ›

MPDL3280A With Chemoradiation for Lung Cancer

NCT02525757

Active Not Recruiting

The goal of this clinical research study is to learn about the safety of adding MDPL3280A to standard chemotherapy (a combination of carboplatin and paclitaxel) and radiation in patients with lung cancer. You are being asked to take part in this study because you have non-small cell lung cancer (NSCLC) that is unresectable (cannot be removed by surgery) and has not spread. This is an investigational study. MPDL3280A is not FDA approved or commercially available. It is currently being used for... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/09/2025

Locations: MD Anderson Cancer Center, Houston, Texas

Conditions: Lung Cancer, Non-Small Cell Lung Cancer

Learn More ›

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

NCT05261399

Recruiting

Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.

Gender:

ALL

Ages:

Between 18 years and 130 years

Trial Updated:

01/09/2025

Locations: Research Site, La Jolla, California +284 locations

Research Site, La Jolla, California

Research Site, Orange City, Florida

Research Site, Orlando, Florida

Research Site, Honolulu, Hawaii

Research Site, Evergreen Park, Illinois

Research Site, Boston, Massachusetts

Research Site, Detroit, Michigan

Research Site, Florham Park, New Jersey

Research Site, New Brunswick, New Jersey

Research Site, New York, New York

Research Site, Canton, Ohio

Research Site, Nashville, Tennessee

Research Site, Berazategui, Not set

Research Site, Buenos Aires, Not set

Research Site, Caba, Not set

Research Site, Cordoba, Not set

Research Site, Florida, Not set

Research Site, La Rioja, Not set

Research Site, Rosario, Not set

Research Site, San Miguel de Tucumán, Not set

Research Site, Viedma, Not set

Research Site, Clayton, Not set

Research Site, Fremantle, Not set

Research Site, Geelong, Not set

Research Site, Liverpool, Not set

Research Site, Southport, Not set

Research Site, Waratah NSW, Not set

Research Site, Westmead, Not set

Research Site, Graz, Not set

Research Site, Salzburg, Not set

Research Site, Wien, Not set

Research Site, Bruxelles, Not set

Research Site, Edegem, Not set

Research Site, Gent, Not set

Research Site, Hasselt, Not set

Research Site, Mons, Not set

Research Site, Roeselare, Not set

Research Site, Sint-Niklaas, Not set

Research Site, Belo Horizonte, Not set

Research Site, Brasilia, Not set

Research Site, Cachoeiro de Itapemirim, Not set

Research Site, Curitiba, Not set

Research Site, Ijuí, Not set

Research Site, Ipatinga, Not set

Research Site, Porto Alegre, Not set

Research Site, Rio De Janeiro, Not set

Research Site, Salvador, Not set

Research Site, São Paulo, Not set

Research Site, Vitória, Not set

Research Site, Haskovo, Not set

Research Site, Pleven, Not set

Research Site, Plovdiv, Not set

Research Site, Sofia, Not set

Research Site, Varna, Not set

Research Site, Vratsa, Not set

Research Site, Calgary, Alberta

Research Site, Mississauga, Ontario

Research Site, Toronto, Ontario

Research Site, Montreal, Quebec

Research Site, Santiago, Not set

Research Site, Temuco, Not set

Research Site, Baoding, Not set

Research Site, Beijing, Not set

Research Site, Bengbu, Not set

Research Site, Changchun, Not set

Research Site, Changsha, Not set

Research Site, Chengdu, Not set

Research Site, Chongqing, Not set

Research Site, Fuzhou, Not set

Research Site, Hangzhou, Not set

Research Site, Hankou,Wuhan, Not set

Research Site, Harbin, Not set

Research Site, Hefei, Not set

Research Site, Jinan, Not set

Research Site, Linyi, Not set

Research Site, Nanchang, Not set

Research Site, Qingdao, Not set

Research Site, Shanghai, Not set

Research Site, Shenyang, Not set

Research Site, Shenzhen, Not set

Research Site, Wuhan, Not set

Research Site, Xi'an, Not set

Research Site, Xiangfan, Not set

Research Site, Xian, Not set

Research Site, Yichang, Not set

Research Site, Zhengzhou, Not set

Research Site, Angers, Not set

Research Site, Bobigny, Not set

Research Site, Bordeaux Cedex, Not set

Research Site, Brest, Not set

Research Site, Creteil, Not set

Research Site, Dijon, Not set

Research Site, Marseille, Not set

Research Site, Montpellier, Not set

Research Site, Paris, Not set

Research Site, Poitiers, Not set

Research Site, Rennes, Not set

Research Site, Rouen, Not set

Research Site, Saint-Herblain, Not set

Research Site, Saint-Quentin, Not set

Research Site, Strasbourg Cedex, Not set

Research Site, Suresnes Cedex, Not set

Research Site, Berlin, Not set

Research Site, Chemnitz, Not set

Research Site, Frankfurt A. Main, Not set

Research Site, Gauting, Not set

Research Site, Homburg, Not set

Research Site, Immenhausen, Not set

Research Site, Löwenstein, Not set

Research Site, Muenster, Not set

Research Site, München, Not set

Research Site, Stuttgart, Not set

Research Site, Wangen, Not set

Research Site, Athens, Not set

Research Site, Chaidari, Not set

Research Site, Heraklion, Not set

Research Site, Larissa, Not set

Research Site, Rio, Not set

Research Site, Thessaloniki, Not set

Research Site, HKG, Not set

Research Site, Hong Kong, Not set

Research Site, Kowloon, Not set

Research Site, Afula, Not set

Research Site, Ashdod, Not set

Research Site, Be'er Ya'akov, Not set

Research Site, Hadera, Not set

Research Site, Jerusalem, Not set

Research Site, Tel Aviv, Not set

Research Site, Avellino, Not set

Research Site, Aviano, Not set

Research Site, Catania, Not set

Research Site, Meldola, Not set

Research Site, Milano, Not set

Research Site, Milan, Not set

Research Site, Modena, Not set

Research Site, Monserrato, Not set

Research Site, Napoli, Not set

Research Site, Orbassano, Not set

Research Site, Padova, Not set

Research Site, Parma, Not set

Research Site, Perugia, Not set

Research Site, Peschiera Del Garda, Not set

Research Site, Roma, Not set

Research Site, Treviso, Not set

Research Site, Bunkyo-ku, Not set

Research Site, Chuo-ku, Not set

Research Site, Fukuoka-shi, Not set

Research Site, Hirosaki-shi, Not set

Research Site, Hiroshima-shi, Not set

Research Site, Iwakuni-shi, Not set

Research Site, Kanazawa-shi, Not set

Research Site, Kashiwa, Not set

Research Site, Kobe-shi, Not set

Research Site, Kobe, Not set

Research Site, Kumamoto-shi, Not set

Research Site, Kurume-shi, Not set

Research Site, Matsuyama, Not set

Research Site, Nagasaki-shi, Not set

Research Site, Okayama-shi, Not set

Research Site, Osaka-shi, Not set

Research Site, Osakasayama-shi, Not set

Research Site, Sakai-shi, Not set

Research Site, Sapporo-shi, Not set

Research Site, Sendai-shi, Not set

Research Site, Sunto-gun, Not set

Research Site, Utsunomiya-shi, Not set

Research Site, Wakayama-shi, Not set

Research Site, Yokohama-shi, Not set

Research Site, Goyang-si, Not set

Research Site, Gyeonggi-do, Not set

Research Site, Incheon, Not set

Research Site, Jinju-si, Not set

Research Site, Seoul, Not set

Research Site, Suwon, Not set

Research Site, Ulsan, Not set

Research Site, Kota Bharu, Not set

Research Site, Kuala Lumpur, Not set

Research Site, Petaling Jaya, Not set

Research Site, Pulau Pinang, Not set

Research Site, Sabah, Not set

Research Site, Amsterdam, Not set

Research Site, Bacolod, Not set

Research Site, Baguio City, Not set

Research Site, Cebu City, Not set

Research Site, Cebu, Not set

Research Site, Davao City, Not set

Research Site, Manila, Not set

Research Site, Quezon City, Not set

Research Site, San Juan, Not set

Research Site, Bialystok, Not set

Research Site, Krakow, Not set

Research Site, Olsztyn, Not set

Research Site, Łódź, Not set

Research Site, Chelyabinsk, Not set

Research Site, Moscow, Not set

Research Site, Saint Petersburg, Not set

Research Site, Tomsk, Not set

Research Site, Singapore, Not set

Research Site, Badajoz, Not set

Research Site, Badalona, Not set

Research Site, Barcelona, Not set

Research Site, Cordoba, Not set

Research Site, Girona, Not set

Research Site, La Coruña, Not set

Research Site, Madrid, Not set

Research Site, Majadahonda, Not set

Research Site, Málaga, Not set

Research Site, Pontevedra, Not set

Research Site, Sabadell, Not set

Research Site, Sevilla, Not set

Research Site, Valencia, Not set

Research Site, Zaragoza, Not set

Research Site, Baden, Not set

Research Site, Basel, Not set

Research Site, Bern, Not set

Research Site, Winterthur, Not set

Research Site, Zürich, Not set

Research Site, Chiayi, Not set

Research Site, Hsinchu, Not set

Research Site, Kaohsiung City, Not set

Research Site, Liuying, Not set

Research Site, Taichung, Not set

Research Site, Taipei 112, Not set

Research Site, Taipei City, Not set

Research Site, Taipei, Not set

Research Site, Bangkok, Not set

Research Site, Chiang Mai, Not set

Research Site, Dusit, Not set

Research Site, Hat Yai, Not set

Research Site, Muang, Not set

Research Site, Mueang Chanthaburi, Not set

Research Site, Adana, Not set

Research Site, Ankara, Not set

Research Site, Edirne, Not set

Research Site, Istanbul, Not set

Research Site, Izmir, Not set

Research Site, Bristol, Not set

Research Site, Leicester, Not set

Research Site, Liverpool, Not set

Research Site, London, Not set

Research Site, Manchester, Not set

Research Site, Newport, Not set

Research Site, Reading, Not set

Research Site, Wolverhampton, Not set

Research Site, Can Tho, Not set

Research Site, Hanoi City, Not set

Research Site, Hanoi, Not set

Research Site, Ho Chi Minh city, Not set

Research Site, Ho Chi Minh, Not set

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

NCT05819892

Recruiting

To learn if chemotherapy given in combination with radiation therapy, followed by maintenance therapy, can help to control endometrial cancer. The safety and effects of this study treatment will also be studied

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

01/09/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Endometrial Cancer

Learn More ›

Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC

NCT02593175

Active Not Recruiting

This phase II trial studies how well panitumumab, carboplatin and paclitaxel work in treating patients with newly diagnosed triple negative breast cancer that is limited to the breast and possibly to the nearby lymph nodes (locally advanced). This treatment study is linked to NCI-2015-00191 protocol, which uses a baseline biopsy to determine the neoadjuvant therapy that matches the sub-type of triple negative breast cancer (TNBC). Immunotherapy with panitumumab, may induce changes in body's immu... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/09/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma

Learn More ›

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

NCT03141359

Active Not Recruiting

This is a single-arm, single-stage Phase II study designed to evaluate the 1-year PFS rate in subjects with locally-advanced NSCLC (stage II/III) and treated with Stereotactic Body Radiation Therapy (SBRT) followed by concurrent mediastinal chemoradiation with or without consolidation chemotherapy. A total of 60 subjects will be enrolled to this study over a 4 year accrual period.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/09/2025

Locations: Levine Cancer Institute, Charlotte, North Carolina

Conditions: Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer

Learn More ›

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

NCT02106988

Recruiting

The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational study. Radiation and chemotherapy are FDA approved and commercially available for patients with Stage 1 and/or 2 NK cell lymphoma. The combination of these therapies given at the same time is investigational. Up to 40 patients will take part in this... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/09/2025

Locations: MD Anderson Cancer Center, Houston, Texas

Conditions: Lymphoma

Learn More ›

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

NCT04592237

Active Not Recruiting

This phase II trial studies the effect of cabazitaxel, carboplatin, and cetrelimab followed by niraparib with or without cetrelimab in treating patients with aggressive variant prostate cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as cabazitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. PARPs are proteins that help repair D... Read More

Gender:

MALE

Ages:

18 years and above

Trial Updated:

01/08/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8

Learn More ›

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

NCT03036488

Active Not Recruiting

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC). After a screening phase of approximately 28 days, each participant will receive neoadjuvant study treatment (Pembrolizumab + Chemotherapy OR Placebo + Chemotherapy) based on the randomization schedule for approximately 24 wee... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/08/2025

Locations: Virginia G. Piper Cancer Center Pharmacy - Scottsdale Healthcare ( Site 0089), Scottsdale, Arizona +192 locations

Virginia G. Piper Cancer Center Pharmacy - Scottsdale Healthcare ( Site 0089), Scottsdale, Arizona

Arizona Oncology Associates PC- HOPE ( Site 8001), Tucson, Arizona

Cedars Sinai Medical Center ( Site 0091), Los Angeles, California

Pacific Cancer Care ( Site 0069), Monterey, California

ICRI ( Site 0072), Whittier, California

University of Colorado Cancer Center ( Site 0021), Aurora, Colorado

Yale University School of Medicine ( Site 0054), New Haven, Connecticut

Christiana Hospital ( Site 0029), Newark, Delaware

Univ of Miami-Sylvester Comprehensive Cancer Center- Kendall satellite ( Site 0079), Miami, Florida

The University of Chicago Medical Center ( Site 0047), Chicago, Illinois

North Shore University Health System ( Site 0081), Evanston, Illinois

Orchard Healthcare Research Inc. ( Site 0049), Skokie, Illinois

Goshen Center for Cancer Care ( Site 0010), Goshen, Indiana

University of Iowa Hospital and Clinics ( Site 0038), Iowa City, Iowa

New England Cancer Specialists ( Site 0005), Scarborough, Maine

Henry Ford Hospital ( Site 0003), Detroit, Michigan

Minnesota Oncology Hematology, PA ( Site 8013), Minneapolis, Minnesota

Rutgers Cancer Institute of New Jersey ( Site 0073), New Brunswick, New Jersey

Broome Oncology, LLC ( Site 8002), Johnson City, New York

Nyack Hospital Infusion Center ( Site 0059), Nyack, New York

TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0044), Cincinnati, Ohio

Oncology Hematology Care, Inc. ( Site 8011), Cincinnati, Ohio

Providence Portland Medical Center ( Site 0052), Portland, Oregon

Northwest Cancer Specialists, P.C. ( Site 8008), Portland, Oregon

Magee - Women's Hospital ( Site 0011), Pittsburgh, Pennsylvania

Rhode Island Hospital ( Site 0060), Providence, Rhode Island

The West Clinic, P.C. ( Site 0078), Germantown, Tennessee

Texas Oncology-Austin Central ( Site 8005), Austin, Texas

Parkland Health and Hospital System ( Site 0093), Dallas, Texas

Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 8006), Dallas, Texas

Simmons Cancer Center ( Site 0094), Dallas, Texas

UT Southwestern Medical Center ( Site 0030), Dallas, Texas

Moncrief Cancer Institute ( Site 0092), Fort Worth, Texas

Texas Oncology-Memorial City ( Site 8003), Houston, Texas

Houston Methodist Cancer Center ( Site 0013), Houston, Texas

Texas Oncology- Plano East ( Site 8010), Plano, Texas

Texas Oncology-San Antonio Northeast ( Site 8012), San Antonio, Texas

Texas Oncology-Tyler ( Site 8007), Tyler, Texas

University of Virginia ( Site 0022), Charlottesville, Virginia

Virginia Cancer Specialists, PC ( Site 8009), Fairfax, Virginia

Bon Secours Cancer Institute Medical Oncology at St. Mary's ( Site 0033), Midlothian, Virginia

Peninsula Cancer Institute, LLC ( Site 0041), Newport News, Virginia

Virginia Oncology Associates ( Site 8000), Norfolk, Virginia

Kadlec Clinic Hematology and Oncology ( Site 0087), Kennewick, Washington

Seattle Cancer Care Alliance ( Site 0068), Seattle, Washington

Medical Oncology Associates (Summit Cancer Centers) ( Site 0014), Spokane, Washington

YVMH dba Vrigina Mason Memorial/North Star Lodge Cancer Center ( Site 8004), Yakima, Washington

Royal North Shore Hospital ( Site 2000), Sydney, New South Wales

Westmead Hospital ( Site 2002), Sydney, New South Wales

Royal Adelaide Hospital ( Site 2008), Adelaide, South Australia

Cabrini Health ( Site 2009), East Malvern, Victoria

Frankston Hospital ( Site 2010), Franskton, Not set

Royal Brisbane and Women s Hospital ( Site 2003), Herston, Not set

St John of God Subiaco Hospital ( Site 2006), Perth, Not set

Hospital Nossa Senhora da Conceicao ( Site 0203), Porto Alegre, Rio Grande Do Sul

UOPECCAN - Uniao Oeste Paranaense de Estudos e Combate ao Cancer ( Site 0206), Cascavel, Not set

Universidade de Caxias do Sul ( Site 0201), Caxias do Sul, Not set

Hospital Erasto Gaertner ( Site 0207), Curitiba, Not set

Instituto do Cancer do Ceara ( Site 0205), Fortaleza, Not set

Hospital Araujo Jorge ( Site 0204), Goiania, Not set

Hospital Sao Lucas da PUCRS ( Site 0200), Porto Alegre, Not set

Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0208), Sao Jose do Rio Preto, Not set

Instituto do Cancer de Sao Paulo - ICESP ( Site 0211), Sao Paulo, Not set

Tom Baker Cancer Centre ( Site 0105), Calgary, Alberta

The Ottawa Hospital - Cancer Care ( Site 0100), Ottawa, Ontario

Princess Margaret Cancer Centre ( Site 0103), Toronto, Ontario

Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0106), Montreal, Quebec

Jewish General Hospital ( Site 0101), Montreal, Quebec

CIUSSS de l'Estrie-CHUS ( Site 0102), Sherbrooke, Quebec

CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0104), Quebec, Not set

Oncomedica S.A. ( Site 0404), Monteria, Cordoba

Oncologos del Occidente S.A. ( Site 0405), Pereira, Risaralda

Hospital Universitario San Ignacio ( Site 0401), Bogota, Not set

Instituto Nacional de Cancerologia [Bogota-Colombia] ( Site 0403), Bogota, Not set

Hemato Oncologos S.A. ( Site 0400), Cali, Not set

Instituto De Cancerologia S.A. ( Site 0406), Medellin, Not set

CHU Jean Minjoz ( Site 0917), Besancon, Not set

Polyclinique Bordeaux Nord Aquitaine ( Site 0911), Bordeaux, Not set

Centre Francois Baclesse ( Site 0907), Caen, Not set

Centre Jean Perrin ( Site 0903), Clermont-Ferrand Cedex 01, Not set

Clinique Victor Hugo ( Site 0901), Le Mans, Not set

Hopital prive du Confluent ( Site 0902), Nantes, Not set

Institut Curie ( Site 0909), Paris, Not set

Hopital Saint Louis ( Site 0908), Paris, Not set

Hopital Diaconesses Croix Saint Simon ( Site 0905), Paris, Not set

CHU de la Miletrie Poitiers ( Site 0913), Poitiers, Not set

Institut Claudius Regaud IUCT Oncopole ( Site 0914), Toulouse Cedex 9, Not set

HELIOS Klinikum Berlin-Buch ( Site 1005), Berlin, Not set

Gynaekologisches Zentrum ( Site 1004), Bonn, Not set

Universitaetsklinikum Erlangen ( Site 1001), Erlangen, Not set

Kliniken Essen Mitte ( Site 1012), Essen, Not set

Universitaetsklinik und Poliklinik Halle/Saale ( Site 1008), Halle, Not set

Universitaetsklinikum Hamburg-Eppendorf ( Site 1007), Hamburg, Not set

Klinikum der Universit. Muenchen ( Site 1002), Muenchen, Not set

Caritasklinik St. Theresia ( Site 1011), Saarbruecken, Not set

Universitaets-Frauenklinik Tuebingen ( Site 1003), Tubingen, Not set

Bon Secours Hospital ( Site 1551), Cork, Not set

St Vincents University Hospital ( Site 1550), Dublin, Not set

Oncology institute ( Site 1601), Beer Sheva, Not set

Assaf Harofeh MC ( Site 1605), Beer Yaakov-Zerifin, Not set

Hadassah Ein Karem - Sharett Institute of Oncology ( Site 1600), Jerusalem, Not set

Rabin-Medical Center ( Site 1604), Petah Tikva, Not set

Sheba Medical Center ( Site 1602), Ramat-Gan, Not set

Sourasky Medical Center ( Site 1603), Tel Aviv, Not set

Istituto Scientifico Romagnolo per Studio e Cura Tumori IRST ( Site 1101), Meldola, FC

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 1103), Brescia, Not set

Ospedale San Luca, AZIENDA USL2 TOSCANA NORD OVEST ( Site 1105), Lucca, Not set

Ospedale Civile di Macerata ( Site 1104), Macerata, Not set

Istituto Europeo di Oncologia ( Site 1106), Milano, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1102), Napoli, Not set

Aichi Cancer Center Hospital ( Site 2502), Nagoya, Aichi

National Cancer Center Hospital East ( Site 2518), Kashiwa, Chiba

National Hospital Organization Hokkaido Cancer Center ( Site 2512), Sapporo, Hokkaido

Hyogo College of Medicine Hospital ( Site 2506), Nishinomiya, Hyogo

Tokai University Hospital ( Site 2517), Isehara, Kanagawa

St. Marianna University School of Medicine Hospital ( Site 2516), Kawasaki, Kanagawa

Kindai University Hospital ( Site 2507), Osakasayama, Osaka

Saitama Medical University International Medical Center ( Site 2513), Hidaka, Saitama

Saitama Cancer Center ( Site 2510), Kitaadachi-gun, Saitama

Shizuoka Cancer Center Hospital and Research Institute ( Site 2514), Sunto-gun, Shizuoka

Chiba Cancer Center ( Site 2519), Chiba, Not set

Hiroshima City Hiroshima Citizens Hospital ( Site 2501), Hiroshima, Not set

Social medical corporation Hakuaikai Sagara Hospital ( Site 2508), Kagoshima, Not set

Kumamoto University Hospital ( Site 2515), Kumamoto, Not set

National Hospital Organization Osaka National Hospital ( Site 2505), Osaka, Not set

National Cancer Center Hospital ( Site 2500), Tokyo, Not set

St.Luke's International Hospital ( Site 2511), Tokyo, Not set

Toranomon Hospital ( Site 2503), Tokyo, Not set

The Cancer Institute Hospital of JFCR ( Site 2509), Tokyo, Not set

Seoul National University Hospital ( Site 2101), Seoul, Not set

Severance Hospital Yonsei University Health System ( Site 2100), Seoul, Not set

Asan Medical Center ( Site 2102), Seoul, Not set

Samsung Medical Center ( Site 2103), Seoul, Not set

Mazowiecki Szpital Onkologiczny ( Site 1713), Wieliszew, Mazowieckie

Centrum Onkologii Instytut im. Marii Skłodowskiej Curie ( Site 1717), Gliwice, Slaskie

Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1708), Bydgoszcz, Not set

Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1712), Bydgoszcz, Not set

Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1701), Gdynia, Not set

Centrum Onkologii Instytut im. Marii Sklodowskiej Curie ( Site 1719), Krakow, Not set

Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli ( Site 1700), Lublin, Not set

Dolnoslaskie Centrum Onkologii. ( Site 1702), Wroclaw, Not set

Fundacao Champalimaud ( Site 2444), Lisboa, Not set

Hospital de Santa Maria, E.P.E. ( Site 2445), Lisboa, Not set

Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 2446), Porto, Not set

Arkhangelsk Clinical Oncological Dispensary ( Site 1810), Arkhangelsk, Not set

Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1805), Chelyabinsk, Not set

Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1806), Kazan, Not set

Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 1801), Moscow, Not set

GBU RO Regional Clinical Oncological Dispensary ( Site 1808), Ryazan, Not set

Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1803), Saint Petersburg, Not set

Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1804), Ufa, Not set

National Cancer Centre Singapore ( Site 2600), Singapore, Not set

ICO L Hospitalet ( Site 1305), Hospitalet de Llobregat, Barcelona

Hospital Quiron de Madrid ( Site 1303), Pozuelo de Alarcon, Madrid

Hospital del Mar ( Site 1306), Barcelona, Not set

Instituto Oncologico Baselga.Hospital Quiron. ( Site 1312), Barcelona, Not set

Hospital General Universitari Vall d Hebron ( Site 1301), Barcelona, Not set

Hospital Universitario Reina Sofia ( Site 1304), Cordoba, Not set

Hospital Universitario Ramon y Cajal ( Site 1300), Madrid, Not set

Complejo Hospitalario Universitario de Santiago ( Site 1308), Santiago de Compostela, Not set

Hospital Universitario Virgen del Rocio ( Site 1314), Sevilla, Not set

Hospital Clinico Univ de Valencia ( Site 1313), Valencia, Not set

Linkopings Universitetssjukhus ( Site 1402), Linkoping, Not set

Karolinska Universitetssjukhuset Solna ( Site 1404), Solna, Not set

Norrlands Universitetssjukhus ( Site 1401), Umea, Not set

Akademiska Sjukhuset ( Site 1403), Uppsala, Not set

Taipei Veterans General Hospital ( Site 2302), Taipei, Beitou

National Cheng Kung University Hospital ( Site 2305), Tainan, Not set

National Taiwan University Hospital ( Site 2301), Taipei, Not set

MacKay Memorial Hospital ( Site 2303), Taipei, Not set

Koo Foundation Sun Yat-Sen Cancer Center ( Site 2304), Taipei, Not set

Linkou Chang Gung Memorial Hospital ( Site 2300), Taoyuan, Not set

Samsun Ondokuz Mayıs Universitesi Tıp Fakultesi Hastanesi ( Site 1910), Samsun, Atakum

Adana Acıbadem Hospital Department of Medical Oncology ( Site 1906), Adana, Not set

Baskent Unıversity Adana Kısla Hospital ( Site 1903), Adana, Not set

Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1912), Ankara, Not set

Abdurrahman Yurtaslan Oncology Training and Research Hospital ( Site 1909), Ankara, Not set

Ozel Medicana International Ankara Hastanesi ( Site 1915), Ankara, Not set

Antalya Memorial Hospital Department of Medical Oncology ( Site 1908), Antalya, Not set

Trakya University Medical Faculty Balkan Oncology Hospital ( Site 1901), Edirne, Not set

Acibadem Altunizade Hastanesi ( Site 1900), Istambul, Not set

İstanbul University Cerrahpaşa Medical Faculty ( Site 1904), Istanbul, Not set

Amerikan Hospital Medical ( Site 1902), Istanbul, Not set

Memorial Sisli Hastanesi ( Site 1913), Istanbul, Not set

Ege University Medical Faculty Tulay Aktas Oncology Hospital ( Site 1905), Izmir, Not set

Izmir Medical Park Hospital Department of Medical Oncology ( Site 1907), Izmir, Not set

Colchester General Hospital ( Site 1508), Colchester, Essex

Barts Cancer Institute ( Site 1500), London, Not set

St George s Hospital ( Site 1516), London, Not set

Maidstone Hospital ( Site 1511), Maidstone, Not set

The James Cook University Hospital ( Site 1515), Middlesbrough, Not set

Nottingham University Hospitals NHS Trust ( Site 1505), Nottingham, Not set

Royal Cornwall Hospitals NHS Trust ( Site 1504), Truro, Not set

Conditions: Triple Negative Breast Neoplasms

Learn More ›

Browse by State

Carboplatin treatment options in Alabama

Carboplatin treatment options in Alaska

Carboplatin treatment options in Arizona

Carboplatin treatment options in Arkansas

Carboplatin treatment options in California

Carboplatin treatment options in Colorado

Carboplatin treatment options in Connecticut

Carboplatin treatment options in Delaware

Carboplatin treatment options in District of Columbia

Carboplatin treatment options in Florida

Carboplatin treatment options in Georgia

Carboplatin treatment options in Hawaii

Carboplatin treatment options in Idaho

Carboplatin treatment options in Illinois

Carboplatin treatment options in Indiana

Carboplatin treatment options in Iowa

Carboplatin treatment options in Kansas

Carboplatin treatment options in Kentucky

Carboplatin treatment options in Louisiana

Carboplatin treatment options in Maine

Carboplatin treatment options in Montana

Carboplatin treatment options in Nebraska

Carboplatin treatment options in Nevada

Carboplatin treatment options in New Hampshire

Carboplatin treatment options in New Jersey

Carboplatin treatment options in New Mexico

Carboplatin treatment options in New York

Carboplatin treatment options in North Carolina

Carboplatin treatment options in North Dakota

Carboplatin treatment options in Ohio

Carboplatin treatment options in Oklahoma

Carboplatin treatment options in Oregon

Carboplatin treatment options in Maryland

Carboplatin treatment options in Massachusetts

Carboplatin treatment options in Michigan

Carboplatin treatment options in Minnesota

Carboplatin treatment options in Mississippi

Carboplatin treatment options in Missouri

Carboplatin treatment options in Pennsylvania

Carboplatin treatment options in Rhode Island

Carboplatin treatment options in South Carolina

Carboplatin treatment options in South Dakota

Carboplatin treatment options in Tennessee

Carboplatin treatment options in Texas

Carboplatin treatment options in Utah

Carboplatin treatment options in Vermont

Carboplatin treatment options in Virginia

Carboplatin treatment options in Washington

Carboplatin treatment options in West Virginia

Carboplatin treatment options in Wisconsin

Carboplatin treatment options in Wyoming